Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

DarioHealth Corp.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

FIRST IN-MARKET ACTIVATION OF DARIO'S GENAI ROADMAP LAYS CLINICAL AND TECHNICAL FOUNDATION FOR A SEAMLESS, CONVERSATIONAL AI EXPERIENCE ACROSS THE ENTIRE DARIO PLATFORM DARIOIQREFLECTS YEARS OF INNOVATION IN DATA SCIENCE, ENGINEERING AND CLINICAL DESIGN BACKED BY DARIO'S PROPRIETARY AI MODELS AND 13 BILLION REAL-WORLD DATA POINTS, FURTHER REINFORCING DARIO'S POSITION AS A LEADER IN DIGITAL HEALTH NEW YORK , DEC. 10, 2025 /PRNEWSWIRE/ -- DARIOHEALTH CORP. (NASDAQ: DRIO) (THE "COMPANY", "DARIOHEALTH" OR "DARIO"), A LEADER IN GLOBAL DIGITAL HEALTH, TODAY ANNOUNCED THE LAUNCH OF THE DARIO HEALTH APP ENHANCED WITH DARIOIQ, THE COMPANY'S NEW ARTIFICIAL INTELLIGENCE ("AI") LAYER, DELIVERED AS A DIRECT-TO-CONSUMER FIRST VERSION FOR AN INITIAL COHORT OF HYPERTENSION MEMBERS WHO ENROLLED TO ACCESS THE NEW EXPERIENCE. THIS LAUNCH MARKS THE FIRST MAJOR MILESTONE IN DARIO'S MULTI-PHASE INTRODUCTION OF CONVERSATIONAL AI DESIGNED TO ENHANCE, NOT REPLACE, THE HUMAN-CENTERED GUIDANCE CENTRAL TO CHRONIC CONDITION MANAGEMENT.

DARIO LAUNCHES DARIOIQ AI INTEGRATION IN DARIO HEALTH APP WITH DIRECT-TO-CONSUMER FIRST VERSION FOR HYPERTENSION MEMBERS

PEER-REVIEWED JMIR CARDIO STUDY DEMONSTRATES REAL-WORLD CLINICAL IMPACT OF DATA-DRIVEN DIGITAL NUDGES ON HYPERTENSION OUTCOMES DATA-DRIVEN ENGAGEMENT TRANSLATES TO LOWER HEALTH RISKS AND DOWNSTREAM COST SAVINGS FOR DARIO CLIENTS RESULTS HIGHLIGHT DARIO'S ABILITY TO DELIVER LASTING IMPACT AND FURTHER CEMENT THE COMPANY'S POSITION AS A PROVEN LEADER IN EVIDENCE-BASED DIGITAL CARE  NEW YORK , DEC. 4, 2025 /PRNEWSWIRE/ -- DARIOHEALTH CORP. (NASDAQ: DRIO) (THE "COMPANY", "DARIOHEALTH" OR "DARIO"), A LEADER IN GLOBAL DIGITAL HEALTH, TODAY ANNOUNCED PUBLICATION OF A NEW PEER-REVIEWED STUDY IN JMIR CARDIO DEMONSTRATING THAT DATA-DRIVEN NUDGES DELIVERED VIA DARIO'S DIGITAL HEALTH PLATFORM ARE ASSOCIATED WITH SIGNIFICANT AND SUSTAINABLE IMPROVEMENTS IN BLOOD PRESSURE ("BP") OUTCOMES. THE STUDY, TITLED " THE IMPACT OF DIGITAL INTERVENTION MESSAGES TARGETING USERS WITH HIGH BLOOD PRESSURE EVENTS: RETROSPECTIVE REAL-WORLD STUDY ," ANALYZED REAL-WORLD BP DATA FROM PLATFORM USERS WHOSE HEALTH WAS TRACKED OVER TIME, COMPARING A COHORT THAT RECEIVED DIGITAL INTERVENTION MESSAGES TO A PROPENSITY-MATCHED CONTROL GROUP.

DARIO'S DATA-DRIVEN DIGITAL HEALTH PLATFORM DELIVERS SIGNIFICANT AND SUSTAINABLE IMPROVEMENTS IN BLOOD PRESSURE: FINDINGS PUBLISHED IN JMIR CARDIO

34 NEW EMPLOYER CLIENTS ADDED IN THE PAST TWO WEEKS EXPECTED TO CONTRIBUTE TO H1 2026 REVENUE DATA-DRIVEN OUTCOMES DRIVE EMPLOYER ADOPTION, HIGHLIGHTING DARIO'S MARKET LEADERSHIP AS PARTNER OF CHOICE, UNDERSCORING EMPLOYER CONFIDENCE, REPEATABILITY AND SCALABILITY NEW YORK , DEC. 2, 2025 /PRNEWSWIRE/ -- DARIOHEALTH CORP. (NASDAQ: DRIO) (THE "COMPANY", "DARIOHEALTH" OR "DARIO"), A LEADER IN GLOBAL DIGITAL HEALTH, TODAY ANNOUNCED THAT IT HAS SECURED 34 NEW EMPLOYER CLIENTS IN THE PAST TWO WEEKS, REACHING A TOTAL OF 79 CLIENTS SIGNED YEAR-TO-DATE, EXCEEDING ITS 2025 TARGET OF 40 NEW CLIENTS BY 98%. THESE NEW AGREEMENTS, WHICH COLLECTIVELY REPRESENT TENS OF THOUSANDS OF COVERED LIVES, FURTHER VALIDATE DARIO'S STRONG PENETRATION, STICKINESS AND REPEATABILITY IN THE MID-SIZE EMPLOYER MARKET.

DARIOHEALTH FAR EXCEEDS 2025 NEW CLIENT TARGET WITH 79 NEW ACCOUNTS SIGNED YEAR-TO-DATE

SANOFI AND SYMPHONY HEALTH TEAMS CONDUCTED THE STUDY DEMONSTRATING HOW DARIO'S DIGITAL, DIABETES INTERVENTION PLATFORM REDUCES REAL-WORLD HEALTHCARE BURDEN AND COST COMPARED TO USUAL CARE REPRESENTING A HIGH-RIGOR, REAL WORLD ANALYSIS, THE STUDY FOUND DARIO USERS, AS COMPARED TO MATCHED INDIVIDUALS RECEIVING USUAL CARE, HAD 23% LOWER HOSPITALIZATION RATES AND 26% LOWER ALL-CAUSE CHARGES MORE FREQUENT ENGAGEMENT ON THE DARIO PLATFORM ASSOCIATED WITH FEWER INPATIENT AND ER EVENTS NEW YORK , NOV. 24, 2025 /PRNEWSWIRE/ --DARIOHEALTH CORP. (NASDAQ: DRIO) (THE "COMPANY", "DARIOHEALTH" OR "DARIO"), A LEADER IN GLOBAL DIGITAL HEALTH, TODAY ANNOUNCED THE PUBLICATION OF A NEW PEER-REVIEWED STUDY IN THE JOURNAL OF MEDICAL INTERNET RESEARCH (JMIR), A HIGHLY INFLUENTIAL DIGITAL HEALTH JOURNAL, EVALUATING HEALTHCARE UTILIZATION AND MEDICAL COSTS AMONG DARIO USERS COMPARED TO MATCHED NON-USERS RECEIVING USUAL CARE. THE STUDY, "EFFECTS OF A DIGITAL HEALTH INTERVENTION FOR ADULTS WITH TYPE 2 DIABETES MELLITUS ON HEALTH CARE RESOURCE USE AND HEALTH CARE CHARGES IN THE UNITED STATES: RETROSPECTIVE COHORT STUDY," WAS NOT AUTHORED BY DARIO, BUT RATHER CONDUCTED BY RESEARCHERS AT SANOFI AND SYMPHONY HEALTH.

DARIOHEALTH ANNOUNCES PUBLICATION OF SANOFI STUDY IN JMIR DEMONSTRATING AN ESTIMATED $5,077 MEDICAL COST SAVINGS PER DARIO DIGITAL HEALTH PLATFORM USER PER YEAR

THIRD QUARTER 2025 REVENUE WAS $5.0 MILLION, COMPARED TO $7.4 MILLION IN THE THIRD QUARTER OF 2024, AND $5.4 MILLION IN THE SECOND QUARTER OF 2025 TARGETING $12.4 MILLION IN NEW BUSINESS, REFLECTING BOTH COMMITTED ANNUAL RECURRING REVENUE ("CARR") AND LATE-STAGE OPPORTUNITIES NEARING COMPLETION; 2026 PIPELINE EXPANDED TO $69 MILLION EXCEEDED 2025 GOAL OF 40 NEW SIGNED ACCOUNTS FOR 2026 REVENUE, WITH 45 NEW SIGNED ACCOUNTS TO DATESEVERAL ALREADY CONTRIBUTING TO 2025 RESULTS; AVERAGE EMPLOYER CUSTOMER SIZE NEARLY DOUBLED WHAT WAS PROJECTED STRONG BUSINESS FUNDAMENTALS IN THE THIRD QUARTER INCLUDING GAAP GROSS MARGIN INCREASE TO 60%, 7 CONSECUTIVE QUARTERS OF 80%+ NON-GAAP GROSS MARGINS ON CORE B2B2C BUSINESS, AND $17.2 MILLION, OR 31%, REDUCTION IN OPERATING EXPENSES FOR THE FIRST NINE MONTHS OF 2025 COMPARED TO THE SAME PERIOD IN 2024 DARIO'S INTEGRATED WHOLE-PERSON DIGITAL HEALTH PLATFORM IS DRIVING ADOPTION AS MORE THAN 50% OF COMPANY'S NEW CLIENTS ARE CHOOSING THE MULTI-CONDITION OFFERINGCOMBINING AI-DRIVEN PERSONALIZATION ACROSS DIABETES, HYPERTENSION, WEIGHT MANAGEMENT, MUSCULOSKELETAL, AND MENTAL HEALTH BACKED BY $31.9 MILLION IN CASH AND CASH EQUIVALENTS ON THE BALANCE SHEET AS OF SEPTEMBER 30, 2025, AND ACCELERATING COMMERCIAL MOMENTUM, DARIO EXPECTS TO REACH CASHFLOW BREAKEVEN BY LATE 2026 TO EARLY 2027 DARIO WILL HOST AN INVESTOR CONFERENCE CALL AND WEBCAST AT 8:30 A.M. ET TODAY NEW YORK , NOV. 13, 2025 /PRNEWSWIRE/ --DARIOHEALTH CORP. (NASDAQ: DRIO) ("DARIO" OR THE "COMPANY"), A LEADER IN THE GLOBAL DIGITAL HEALTH MARKET, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, ALONG WITH STRATEGIC AND COMMERCIAL UPDATES.

DARIOHEALTH REPORTS THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

ANALYSIS BASED ON CLAIMS DATA HIGHLIGHTS SIGNIFICANT COST SAVINGS, ESPECIALLY AMONG HIGH-RISK MEMBERS NEW YORK , NOV. 12, 2025 /PRNEWSWIRE/ -- DARIOHEALTH CORP. (NASDAQ: DRIO) (THE "COMPANY", "DARIOHEALTH" OR "DARIO"), A LEADER IN GLOBAL DIGITAL HEALTH, TODAY ANNOUNCED THE PRESENTATION OF RESEARCH ON NEW REAL-WORLD EVIDENCE OF MEDICAL COST REDUCTION AT ISPOR EUROPE 2025, ONE OF THE WORLD'S PREMIER HEALTH ECONOMICS AND OUTCOMES RESEARCH CONFERENCES, CURRENTLY TAKING PLACE IN GLASGOW, SCOTLAND. THE STUDY, TITLED "PRELIMINARY OBSERVATIONAL ANALYSIS OF DIGITAL HEALTH PLATFORM ASSOCIATED WITH MEDICAL COST CHANGES IN EMPLOYER POPULATION," REPRESENTS DARIO'S FIRST PUBLICATION USING MEDICAL CLAIMS DATA TO EVALUATE THE ECONOMIC IMPACT OF ITS MULTI-CONDITION DIGITAL HEALTH PLATFORM (DARIO HAS PREVIOUSLY COLLABORATED WITH CLIENTS TO PRODUCE RESEARCH DEMONSTRATING CLAIMS-BASED COST REDUCTION).

DARIOHEALTH PRESENTS NEW DATA DEMONSTRATING SIGNIFICANT REDUCTION IN MEDICAL COSTS AMONG EMPLOYER POPULATIONS USING ITS DIGITAL HEALTH PLATFORM

COMPANY TO HOST CONFERENCE CALL AND WEBCAST AT 8:30 A.M. EASTERN TIME NEW YORK , NOV. 6, 2025 /PRNEWSWIRE/ --DARIOHEALTH CORP. (NASDAQ: DRIO) ("DARIO" OR THE "COMPANY"), A LEADER IN THE GLOBAL DIGITAL HEALTH MARKET, ANNOUNCED TODAY THAT IT WILL RELEASE ITS FINANCIAL RESULTS FOR THE 3RD QUARTER ENDED SEPTEMBER 30 TH, 2025 AND WILL HOST A CONFERENCE CALL AND WEBCAST AT 8:30 A.M.

DarioHealth Corp.

DRIO

Price

Financials Overview

Financial Reports

No items found.

Press Releases

DarioHealth Corp.

DRIO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

DRIO